Dexamethasone - CAS 50-02-2

Quick Inquiry

Name:
* Email:
* Service & Products of Interest:
* Quantity:
* Verification code:
Please input "bocsci" as verification code.
Category
APIs
Product Name
Dexamethasone
Catalog Number
50-02-2
CAS Number
50-02-2
Molecular Weight
392.46
Molecular Formula
C22H29FO5
Quality Standard
BP/USP
COA
Inquire
MSDS
Inquire
Structure
CAS 50-02-2 Dexamethasone
Specification
Purity
>99%
Appearance
White or off-white crystalline powder
Related Products
Reference Reading
1.Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial
Hye Jin Kim & Sung-Soo Yoon & Dong Soon Lee. Ann Hematol (2012) 91:249–256
The vincristine, adriamycin, and dexamethasone (VAD) combination regimen has been commonly used as an induction chemotherapy for those patients who are potential candidates for ASCT, but novel agents such as thalidomide, bortezomib, and lenalidomide are recently replacing VAD due to their increased efficacy. Thalidomide is an oral agent with immunomodulatory and antiangiogenic properties, and it has shown significant activity for patients with refractory multiple myeloma as a single agent, and thalidomide combined with dexamethasone has shown an increased response rate for patients with refractory or newly diagnosed multiple myeloma. Bortezomib is a selective and reversible proteasome inhibitor that inhibits the degradation of ubiquitinated target proteins. It has shown a high response rate for patients with relapsed or refractory multiple myeloma in SUMMIT and CREST trials. The addition of dexamethasone to bortezomib has been associated with an improved response without prohibitive toxicity. For newly diagnosed patients with multiple myeloma, bortezomib alone, and in combination with dexamethasone, has achieved 90% response rate or better including complete response (CR) + near CR rate of 20% in various trials [20]. A recent phase I/II study with bortezomib, thalidomide, and dexamethasone (VTD) reported remarkable efficacy in patients with advanced and refractory myeloma with a partial remission (PR) rate of 63% and a near CR rate of 22% .
2005 - BOC Sciences | All rights reserved
DOWNLOAD